Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH1-Mutated Malignancies”

81 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 81 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07664839
What this trial is testing

Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

Who this might be right for
Acute Myeloid LeukemiaNPM1 MutationIDH1 Mutation+1 more
Shen yang 148
Not applicableApproved For MarketingNCT05592743
What this trial is testing

Vorasidenib Expanded Access Program

Who this might be right for
GliomaRecurrenceDisease Attributes+10 more
Servier
Testing effectiveness (Phase 2)Looking for participantsNCT03471260
What this trial is testing

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaHematopoietic and Lymphoid System NeoplasmMyelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center 96
Early research (Phase 1)Active Not RecruitingNCT03749187
What this trial is testing

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Who this might be right for
GlioblastomaIDH1 Gene MutationIDH2 Gene Mutation+7 more
University of California, San Francisco 78
Not applicableLooking for participantsNCT07142226
What this trial is testing

Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC

Who this might be right for
Biliary Tract Cancer
CHA University 200
Not applicableUnknownNCT02333513
What this trial is testing

Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Who this might be right for
Recurrent High-grade Glioma
Hebei Yanda Hospital 100
Early research (Phase 1)Looking for participantsNCT05873686
What this trial is testing

Clinical Study of NXP900 in Subjects With Advanced Cancers

Who this might be right for
Advanced Solid TumorNSCLC (Non-small Cell Lung Cancer)Renal Cancer+3 more
Nuvectis Pharma, Inc. 140
Testing effectiveness (Phase 2)Looking for participantsNCT07471841
What this trial is testing

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Who this might be right for
IDH1 MutationRelapsed / Refractory AML
Timothy Pardee 25
Very early researchActive Not RecruitingNCT05406700
What this trial is testing

Niraparib In Recurrent IDH 1/2 Gliomas

Who this might be right for
Low-grade GliomaIDH2 Gene MutationRecurrent Glioma+2 more
Massachusetts General Hospital 16
Not applicableLooking for participantsNCT07151118
What this trial is testing

CtDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
CHA University 100
Testing effectiveness (Phase 2)WithdrawnNCT06597734
What this trial is testing

Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Who this might be right for
Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT03503409
What this trial is testing

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 68
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07463768
What this trial is testing

Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

Who this might be right for
Acute Myeloid Leukemia
French Innovative Leukemia Organisation 60
Early research (Phase 1)Looking for participantsNCT07006688
What this trial is testing

An IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

Who this might be right for
IDH1-Mutated Malignancies
Servier Bio-Innovation LLC 30
Not applicableStudy completedNCT06181734
What this trial is testing

Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC

Who this might be right for
Acute Myeloid Leukemia (AML)
iOMEDICO AG 8
Not applicableUnknownNCT04369287
What this trial is testing

Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaIDH1 Gene MutationIDH2 Gene Mutation
Istituto Clinico Humanitas 654
Not applicableStudy completedNCT01703962
What this trial is testing

Non Invasive IDentification of Gliomas With IDH1 Mutation

Who this might be right for
Non Invasive Diagnosis of Glioma
Institut National de la Santé Et de la Recherche Médicale, France 6
Testing effectiveness (Phase 2)WithdrawnNCT02987010
What this trial is testing

Phase 2 Study of IDH305 in Low Grade Gliomas

Who this might be right for
Glioma
University of Texas Southwestern Medical Center
Testing effectiveness (Phase 2)Study completedNCT04056910
What this trial is testing

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Who this might be right for
Advanced Solid TumorIDH1 MutationGlioma
Jason J. Luke, MD 15
Testing effectiveness (Phase 2)Looking for participantsNCT06782542
What this trial is testing

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaIDH1 Mutation
Justin Watts, MD 16
Next Page